Clinical Scorecard: Continuous Glucose Monitoring in Relation to Long-Term Glycemic Control and Kidney Outcomes
At a Glance
Category
Detail
Condition
Type 2 diabetes; study of the association of real-time continuous glucose monitoring (rtCGM) with glycemic and kidney outcomes.
Key Mechanisms
CGM uses subcutaneous sensors to measure interstitial-fluid glucose. The source describes rtCGM as delivering immediate feedback and intermittently scanned CGM as requiring manual scanning.
Target Population
Adults aged 19 years or older with type 2 diabetes, no prior CGM exposure, and either HbA1c greater than 8% within the preceding 12 months or a hypoglycemia-related emergency department visit or inpatient admission within the preceding 36 months.
Care Setting
Observational comparative-effectiveness study using electronic health records and durable medical equipment claims at Kaiser Permanente Northern California.
Key Highlights
The study emulated a target trial comparing initiation and continued use of rtCGM with no CGM use.
Outcomes included HbA1c, urinary albumin-creatinine ratio (UACR), and estimated glomerular filtration rate (eGFR).
Monthly risk sets with temporally matched controls were assembled from January 2015 through June 2023.
Follow-up was planned for up to 36 months; the supplied excerpt does not provide the full censoring details.
The supplied article text describes the study design and outcomes but does not report study results.
Guideline-Based Recommendations
Diagnosis
Target-trial eligibility required type 2 diabetes and either HbA1c greater than 8% within the preceding 12 months or a hypoglycemia-related emergency department visit or inpatient admission within the preceding 36 months.
Management
The study compared initiating and maintaining rtCGM with not initiating CGM; the supplied text does not state clinical treatment recommendations.
Monitoring & Follow-up
Study outcomes were HbA1c, UACR, and eGFR; the supplied excerpt does not specify the measurement setting or follow-up interval schedule.
Risks
The authors noted limited prior evidence on long-term CGM effects and whether CGM preserves kidney function or reduces kidney damage.
The study used observational data and target trial emulation to address limitations including time-varying confounding.
Patient & Prescribing Data
Adults aged 19 years or older with type 2 diabetes, no previous CGM exposure, and either poor glycemic control or a history of hypoglycemia as defined by the study.
rtCGM initiation was identified through durable medical equipment claims for specified devices or supplies. The emulated per-protocol comparison was continued rtCGM use versus no CGM use.
Clinical Best Practices
Interpret the study as an observational target trial emulation, not a randomized clinical trial.
The analysis restricted CGM exposure to rtCGM to reduce heterogeneity.
Controls were sampled from monthly risk sets and assigned baseline dates within the selection month to match initiators temporally.
The study followed STROBE and TARGET reporting guidance.
A healthy lifestyle was associated with a smaller loss of disease-free life expectancy related to social isolation, but the same pattern did not hold for loneliness.
Adults assigned to nonnutritive sweetened beverages or water maintained weight reductions through 104 weeks, with no statistically significant difference between groups.
